Stockreport

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Werewolf Therapeutics, Inc.  (HOWL) 
PDF — Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — — Multiple presentations of [Read more]